BrainsWay

Update in progress

BWAY (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

BrainsWay Ltd. develops and markets noninvasive neurostimulation therapies for mental health and neurology. Its Deep Transcranial Magnetic Stimulation (dTMS) platform treats major depressive disorder, anxiety, OCD, smoking, bipolar disorder, PTSD, schizophrenia, Alzheimer’s, autism, chronic pain, MS, stroke rehab, and Parkinson’s. Serving clinicians in hospitals and medical centers worldwide, BrainsWay was founded in 2003 and is headquartered in Jerusalem, Israel.

Company score

Sentiment: 0.55; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.54; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.13; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.19; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.37; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive